Rosina Schiff, DO
Pulmonary Disease · Omaha, NENPI 1033648308
Payments from drug & device makers
What this record shows
This record is dominated by education: $4,191 of the $6,022 with a category attached, or 69.6%. Intuitive Surgical accounts for 80.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $5,072 and has fallen 92.7% since, to $371 in 2025.
Across 61 payments — averaging $98.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Astellas Pharma US Inc$191
- Pulmonx Corporation$136
- AstraZeneca$124
- Insmed, Inc.$102
- Grifols USA, LLC$100
- plus $539 from 14 others
What the payments were for
- Travel & lodging$73812%
- Food & beverage$1,09318%
- Education$4,19170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $4,829 |
| Astellas Pharma US Inc | 3 | $191 |
| Pulmonx Corporation | 1 | $136 |
| AstraZeneca | 8 | $124 |
| Insmed, Inc. | 4 | $102 |
| Grifols USA, LLC | 4 | $100 |
| Jazz Pharmaceuticals Inc. | 4 | $81 |
| Actelion Pharmaceuticals US, Inc. | 4 | $72 |
| Sanofi | 3 | $52 |
| Harmony Biosciences LLC | 2 | $44 |
| Amgen | 3 | $43 |
| United Therapeutics Corporation | 2 | $40 |
| Philips North America LLC | 2 | $34 |
| Baxter Healthcare | 2 | $33 |
| Boehringer Ingelheim | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Verona Pharma, Inc. | 1 | $17 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,022 in reported general payments places this provider in the 70th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $22,396 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,675 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $7,069 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,304 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $385 |
| Furosemide | 25 | $91 |
| Prednisone | 26 | $74 |
| Azithromycin | 14 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSymbicort | $124 | $4,30419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Michael SanleyOmaha$17K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Palvannanathan GanesanOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.